Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)

NCT03866174 is registered in ClinicalTrials.gov with Usona Institute as lead sponsor.

NCT NCT03866174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03866174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)
Lead sponsor
Usona Institute
Phase
Phase 2
Overall status
Completed
Start date
January 23, 2020
Completion date
June 28, 2022
Enrollment
347 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major